Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Momenta Pharmaceuticals, Inc. (MNTA) is “One to Watch”

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) is a biotechnology company focused on the development of generic versions of complex drugs. The company is in the business of discovering and developing new therapies for oncology and autoimmune indications. Currently, the company has four products still in the development stage (hsIVIg, M230, five biosimilar programs, and M834), two in clinical stage one trials (M281 and M923), one in the process of being BLA and NDA accepted (40 mg/ml COPAXONE®), and two already being sold at market (LOVENOX® and 20 mg/ml COPAXONE®).

Most recently, the company announced positive top-line phase III results for M923, a biosimilar HUMIRA® which is used in patients with moderate to severe chronic plaque psoriasis. Out of all the subjects who took part in the study, 75% showed a reduction in the psoriasis area and the severity index (PASI-75) was equal between both M923 and HUMIRA® after the 16-week treatment. Although the drug has been developed and commercialized by both MNTA and Baxter Bioscience, now part of Shire, MNTA is expected to take over M923 in order for Shire to continue its focus on treating patients with rare diseases.

Aegis Capital Corp. (, initiated coverage on the company on November 22, 2016, giving MNTA a ‘Hold’ rating with a price target of $15 based on the fact that the commercial launch of 40 mg Glatopa (a generic equivalent of COPAXONE®) is not expected for 2017 and that phase III trial results had not yet been disclosed. With these now showing promising results, it is worth noting that Aegis Capital Corp. stated, “If positive the M923 timeline has the potential to include a submission for marketing approval around mid-2017”.

According to Baseball News Source (, Momenta Pharmaceuticals, Inc. has been on the radar for many analysts, receiving a consensus rating of ‘Buy’ from the 10 analysts covering the stock. The average price target from brokers for the next year is $16, with one research analyst giving the company a ‘Sell’ rating, three giving it a ‘Hold’ rating, and six offering a ‘Buy’ recommendation. Analysts included Stifel Nicolaus, Maxim Group, Zacks Investment Research, Cowen and Company, and Aegis Capital Corp., among others.

In addition to the above, a number of investors have recently changed their stakes in the company’s stock. Pacad Investment Ltd., Jane Street Group LLC, Dynamic Technology Lab Private Ltd., Profund Advisors LLC, and Cornerstone Capital Management Holdings LLC acquired new stakes in Momenta Pharmaceuticals, Inc., all of which were worth more than $100,000 individually. Hedge funds and investors now own approximately 85% of MNTA’s stock.

Momenta reported its financial results for the nine months ended September 30, 2016 early last month. For the nine-month period, the company reported total revenue of just over $75 million, which included just under $59 million in revenues from Sadoz’s sale of Glatopa®. Recently, the company traded up by more than 0.70%, reaching $14.15 per share. As of the end of September, Momenta had cash and cash equivalents of $309 million. The company has a market cap of $975.74 million with revenue up 2067.7%, as compared to the same time last year.

For more information, visit the company’s website at

This entry was posted in Ones to Watch. Bookmark the permalink.

Comments are closed.